For most adults prescribed modafinil, 200 mg per day is the standard dose. Higher doses have been studied but rarely improve wakefulness further and increase the risk of side effects. Clinical guidelines reflect what has been tested in controlled trials and proven effective in routine use.
Standard prescribed dose
Modafinil is typically prescribed at 200 mg once daily across approved indications. Patients with narcolepsy or obstructive sleep apnea take it in the morning. Patients with shift work disorder take it about one hour before their work shift begins. Controlled trials support this dosing, and prescribing guidelines reflect these findings.
At 200 mg, most patients achieve meaningful improvements in alertness without excessive stimulation or disruption of nighttime sleep.
Maximum studied doses
Clinical trials have evaluated doses up to 400 mg per day with acceptable tolerability. These studies have not demonstrated consistent additional benefit above 200 mg for most patients. The 400 mg dose represents the upper boundary of clinical research rather than a routine target.
Prescriptions exceeding 200 mg reflect individual clinical circumstances under specialist care.
Limited benefit from higher doses
Higher doses of modafinil do not produce proportional increases in wakefulness. Once the drug engages wakefulness pathways sufficiently, additional exposure does not reliably improve alertness or focus. Higher doses do increase the frequency of adverse effects, including insomnia or delayed sleep onset, anxiety or restlessness, headache and nausea, appetite suppression, and cardiovascular stimulation in susceptible individuals.
Clinicians treat 200 mg as the practical ceiling for standard use.
Dose reductions for specific populations
Some patients require lower doses, not higher ones. Severe liver impairment reduces modafinil clearance significantly. The recommended dose in this population is half the standard amount, typically no more than 100 mg per day. Older adults may also clear the drug more slowly, supporting lower starting doses and closer monitoring.
Modafinil is avoided during pregnancy. Post-marketing surveillance has identified an increased risk of congenital malformations, including heart defects and orofacial clefts.
Split dosing in narcolepsy
Patients with narcolepsy sometimes experience adequate morning alertness followed by sleepiness returning in the late afternoon or evening. Split dosing has been evaluated specifically in this situation.
A 2005 study by Schwartz and colleagues compared once-daily and split-dose regimens in 56 narcolepsy patients who had satisfactory early responses to modafinil but persistent late-day sleepiness. Split-dose regimens (either 400 mg total as 200 mg morning/200 mg midday, or 600 mg total as 400 mg morning/200 mg midday) significantly improved late afternoon and evening wakefulness compared to 200 mg once daily. All regimens were well tolerated with no increase in adverse events.
This approach addresses a specific clinical problem in a defined patient population. It requires careful timing to avoid sleep disruption and is typically managed under specialist supervision rather than as routine practice.
Practical considerations
Most patients respond well to 200 mg taken early in the day to protect nighttime sleep. When alertness declines in the late afternoon, adjusting timing or considering split dosing under medical supervision is preferable to simply increasing the total dose. Combining modafinil with other stimulants without medical guidance increases risks of adverse effects and sleep disturbance.
Dose adjustments should occur in consultation with a healthcare professional who can assess individual response, monitor for side effects, and adjust treatment as needed.
Effectiveness of standard dosing
In clinical practice, 200 mg per day is the effective dose of modafinil for most adults. Doses up to 400 mg per day have been studied without consistent evidence of superior efficacy. Higher doses carry increased risk of adverse effects. Dosing beyond standard recommendations requires specific clinical rationale and medical oversight.
This information is based on clinical evidence and does not replace medical advice. Consult a qualified healthcare professional for individual guidance.
Sources and references
- Schwartz, J. R., Feldman, N. T., & Bogan, R. K. (2005). Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. Journal of Neuropsychiatry and Clinical Neurosciences, 17(3), 405–412. https://doi.org/10.1176/jnp.17.3.405
(Erratum published 2005, Journal of Neuropsychiatry and Clinical Neurosciences, 17(4), 561) - Greenblatt, K., & Adams, N. (2023). Modafinil. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK531476/
- U.S. Food and Drug Administration. (2015). PROVIGIL® (modafinil) tablets, for oral use, C-IV: Prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf